Polymorphisms in XPC provide prognostic information in acute myeloid leukemia

Area of Science:

• Oncology
• Genetics
• Pharmacogenomics

Background:

• Acute myeloid leukemia (AML) is a prevalent adult leukemia.
• Cytosine arabinoside-based chemotherapy is a primary treatment for AML.
• Genetic variations in DNA repair pathways, like nucleotide excision repair (NER), may influence chemotherapy efficacy.

Purpose of the Study:

• To investigate the association between specific single nucleotide polymorphisms (SNPs) in the NER pathway (ERCC5 and XPC genes) and treatment outcomes in AML patients.
• To evaluate the role of these SNPs in predicting response to cytosine arabinoside-based chemotherapy.

Main Methods:

• Genotyping of six SNPs (ERCC5rs76871136, ERCC5rs77569659, ERCC5rs873601, XPCrs2228000, XPCrs2228001, XPCrs1870134) in 151 Chinese AML patients.
• Analysis of genotype distribution across cytogenetic risk and gender groups.
• Statistical correlation analysis between SNPs and chemotherapy response.

Main Results:

• The distribution of XPCrs1870134 genotypes differed significantly across cytogenetic risk groups (P=0.04).
• A significant correlation was observed between XPCrs2228001 polymorphisms and gender (P=0.03).
• Patients with variant alleles of XPCrs2228001 showed a better response to chemotherapy compared to those without.

Conclusions:

• XPC gene polymorphisms, particularly XPCrs2228001, may serve as important predictive markers for treatment outcomes in Chinese AML patients.
• No significant association was found between ERCC5 polymorphisms and AML treatment response in this cohort.